Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.31
FLDM's Cash-to-Debt is ranked lower than
83% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. FLDM: 0.31 )
Ranked among companies with meaningful Cash-to-Debt only.
FLDM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31  Med: 1.01 Max: No Debt
Current: 0.31
Equity-to-Asset 0.17
FLDM's Equity-to-Asset is ranked lower than
87% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. FLDM: 0.17 )
Ranked among companies with meaningful Equity-to-Asset only.
FLDM' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.63  Med: 0.17 Max: 0.89
Current: 0.17
-7.63
0.89
Piotroski F-Score: 2
Altman Z-Score: -1.81
Beneish M-Score: -3.48
WACC vs ROIC
13.89%
-35.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -70.07
FLDM's Operating Margin % is ranked lower than
72% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. FLDM: -70.07 )
Ranked among companies with meaningful Operating Margin % only.
FLDM' s Operating Margin % Range Over the Past 10 Years
Min: -323.38  Med: -44.12 Max: -26.2
Current: -70.07
-323.38
-26.2
Net Margin % -72.75
FLDM's Net Margin % is ranked lower than
71% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. FLDM: -72.75 )
Ranked among companies with meaningful Net Margin % only.
FLDM' s Net Margin % Range Over the Past 10 Years
Min: -349.84  Med: -51.39 Max: -23.22
Current: -72.75
-349.84
-23.22
ROE % -90.60
FLDM's ROE % is ranked lower than
83% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. FLDM: -90.60 )
Ranked among companies with meaningful ROE % only.
FLDM' s ROE % Range Over the Past 10 Years
Min: -90.6  Med: -40.19 Max: -16.77
Current: -90.6
-90.6
-16.77
ROA % -22.44
FLDM's ROA % is ranked lower than
63% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. FLDM: -22.44 )
Ranked among companies with meaningful ROA % only.
FLDM' s ROA % Range Over the Past 10 Years
Min: -67.71  Med: -32.82 Max: -13.71
Current: -22.44
-67.71
-13.71
ROC (Joel Greenblatt) % -270.66
FLDM's ROC (Joel Greenblatt) % is ranked lower than
70% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. FLDM: -270.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FLDM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -448.22  Med: -231.92 Max: -138.28
Current: -270.66
-448.22
-138.28
3-Year Revenue Growth Rate 8.80
FLDM's 3-Year Revenue Growth Rate is ranked higher than
64% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. FLDM: 8.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
FLDM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -40.9 Max: 20.4
Current: 8.8
0
20.4
3-Year EBITDA Growth Rate 53.00
FLDM's 3-Year EBITDA Growth Rate is ranked higher than
96% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. FLDM: 53.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
FLDM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -56.65 Max: 53
Current: 53
0
53
3-Year EPS without NRI Growth Rate 59.10
FLDM's 3-Year EPS without NRI Growth Rate is ranked higher than
94% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. FLDM: 59.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
FLDM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -55.3 Max: 59.1
Current: 59.1
0
59.1
GuruFocus has detected 5 Warning Signs with Fluidigm Corp $FLDM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FLDM's 10-Y Financials

Financials (Next Earnings Date: 2017-05-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

FLDM Guru Trades in Q1 2016

Columbia Wanger 2,056,004 sh (+14.94%)
PRIMECAP Management 4,266,432 sh (unchged)
Jim Simons 108,000 sh (-47.32%)
Eaton Vance Worldwide Health Sciences Fund 527,700 sh (-19.19%)
» More
Q2 2016

FLDM Guru Trades in Q2 2016

Jim Simons 260,100 sh (+140.83%)
Eaton Vance Worldwide Health Sciences Fund Sold Out
PRIMECAP Management 4,250,732 sh (-0.37%)
Columbia Wanger 1,777,282 sh (-13.56%)
» More
Q3 2016

FLDM Guru Trades in Q3 2016

Jim Simons 370,300 sh (+42.37%)
PRIMECAP Management 4,265,332 sh (+0.34%)
Columbia Wanger Sold Out
» More
Q4 2016

FLDM Guru Trades in Q4 2016

Jim Simons 451,300 sh (+21.87%)
PRIMECAP Management 4,295,532 sh (+0.71%)
» More
» Details

Insider Trades

Latest Guru Trades with FLDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NAS:TRIB, NAS:VRML, NAS:TTOO, NAS:CTSO, NAS:AIQ, NAS:PMD, AMEX:SENS, AMEX:VNRX, NAS:FLGT, NAS:CGIX, OTCPK:CBIS, NAS:QTNT, OTCPK:EDTXF, NAS:CEMI, NAS:HTGM, NAS:BIOC, AMEX:PTN, OTCPK:PRFMF, OTCPK:SYGWF, NAS:TROV » details
Traded in other countries:FLB.Germany,
Headquarter Location:USA
Fluidigm Corp creates, manufactures, and markets technologies and life-science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon microfluidics and mass cytometry technologies.

Fluidigm manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies. Fluidigm sells instruments and consumables, including integrated fluidic circuits, assays, and reagents. Slightly more than half of the firm's revenue comes from the sale of instruments. Fluidigm primarily sells its products to academic institutions, clinical laboratories, and biopharmaceutical companies. The majority of Fluidigm's revenue is generated in the United States and Europe.

Top Ranked Articles about Fluidigm Corp

Fluidigm to Report Q1 2017 Financial Results and Host Conference Call
Nicolas Barthelemy and Carlos Paya Join Fluidigm Board of Directors

SOUTH SAN FRANCISCO, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Nicolas Barthelemy and Dr. Carlos Paya have been appointed to its Board of Directors.
Barthelemy brings over 25 years of health care industry experience to the Fluidigm Board, having served in multiple senior executive roles in the biopharmaceutical, life science tools, and molecular diagnostics sectors. He previously served as President and CEO of Biotheranostics, a privately held molecular diagnostics company, from 2014 until February 2017. Just prior to that, he served as President of Global Commercial Operations at Life Technologies, a $4 billion life science industry leader that was acquired by Thermo Fisher Scientific in 2014.  Prior to that position, he led the $850 million Cell Systems Division for five years at Life Technologies.  Before Life Technologies, Barthelemy was with Biogen for eight years in operational and commercial roles of increasing responsibility, including Vice President of Manufacturing. He began his career with Merck & Co., Inc. as a Project Engineer in the Vaccine Division. Barthelemy currently also serves on the Board of Directors of Repligen Corporation and he was on the Board of Essen BioScience, a privately held life science company, until its recent acquisition by Sartorius AG.  He received an M.S. in chemical engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et de Chimie Industrielles in Paris. “I am very excited to be joining Fluidigm at a critical juncture in its history,” said Barthelemy. “Fluidigm is in the middle of a business transformation that requires balancing investments in innovation, commercial execution, and operational excellence.  I share their enthusiasm for building the next generation of automated mass cytometry and genomics workflow solutions for life science and clinical markets.  I see tremendous potential in both areas.” Dr. Paya brings to the Board over 15 years of senior executive experience in the large, mid-cap, and small-cap biopharmaceutical industries, combined with a prolific scientific background and a track record of leading high-impact innovation. Dr. Paya currently serves as President, Chief Executive Officer, and Director of Immune Design Corp., a clinical-stage immunotherapy company focused on oncology. He previously served as President of Elan Corporation, a pharmaceutical corporation later acquired by Perrigo Company, from 2008 to 2011. Before joining Elan Corporation, Dr. Paya was at Eli Lilly & Company from 2001 to 2008 as Vice President of Lilly Research Laboratories. From 1991 to 2001, Dr. Paya was Professor of Medicine, Immunology, and Pathology and Vice Dean of the Clinical Investigation Program at the Mayo Clinic in Rochester, Minnesota. He received his M.D. and Ph.D. degrees from the University of Madrid and underwent postdoctoral training at the Institute Pasteur in Paris. “Fluidigm has breakthrough technologies that will shape how scientific discoveries are developed and applied to human health,” said Dr. Paya. “Joining a company with such a wide portfolio of industry-leading tools and a passion to innovate is a rare opportunity.  In particular, I believe I can help them execute in a manner that reflects the business and scientific needs of oncology.” “We are thrilled to welcome both Nicolas and Carlos to the Fluidigm Board of Directors,” said Christopher Linthwaite, President and CEO of Fluidigm. “Nicolas has a strong track record in driving sustainable growth and business turnarounds. His deep expertise in commercial and operational success in the life sciences industry is particularly relevant to our organizational goals. Carlos is a seasoned CEO, executive leader and world-class researcher with expertise in immunology and oncology. His academic and industrial experiences in these disease research areas are invaluable as we continue to innovate for these high-impact markets. Both of these new members will be instrumental in helping us accelerate several key elements of our business strategy and position the Fluidigm business for long-term success.” About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures. We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts. Fluidigm and the Fluidigm logo are registered trademarks of Fluidigm Corporation. Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding changes in operations, development of next-generation products, and the ability of management personnel and our board of directors to contribute to the growth of Fluidigm’s business. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by these forward-looking statements, including (among others) risks relating to research and development activities and the growth of new and developing markets, Fluidigm’s ability to successfully launch new products and applications, and competition in Fluidigm’s primary markets. Information on these and additional risks, uncertainties, and other information affecting Fluidigm business and operating results are contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2016, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Contact:

Fluidigm Corporation
Michaeline Bunting
Sr. Director, Marketing
Fluidigm Corporation
650 737 4190
[email protected]

Read more...
Columbia Wanger Sold 2 Stakes in September Divested holdings were in diagnostics and research industry
Columbia Wanger (Trades, Portfolio) sold two stakes from its portfolio on Sept. 30. Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.81
FLDM's PB Ratio is ranked higher than
57% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. FLDM: 2.81 )
Ranked among companies with meaningful PB Ratio only.
FLDM' s PB Ratio Range Over the Past 10 Years
Min: 1.46  Med: 4.65 Max: 12.54
Current: 2.81
1.46
12.54
PS Ratio 1.36
FLDM's PS Ratio is ranked higher than
79% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. FLDM: 1.36 )
Ranked among companies with meaningful PS Ratio only.
FLDM' s PS Ratio Range Over the Past 10 Years
Min: 0.93  Med: 5.84 Max: 16.74
Current: 1.36
0.93
16.74
EV-to-EBIT -4.22
FLDM's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. FLDM: -4.22 )
Ranked among companies with meaningful EV-to-EBIT only.
FLDM' s EV-to-EBIT Range Over the Past 10 Years
Min: -67.7  Med: -14.3 Max: -3.6
Current: -4.22
-67.7
-3.6
EV-to-EBITDA -5.58
FLDM's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. FLDM: -5.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
FLDM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -80.2  Med: -15.7 Max: -4.8
Current: -5.58
-80.2
-4.8
Current Ratio 3.28
FLDM's Current Ratio is ranked higher than
61% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. FLDM: 3.28 )
Ranked among companies with meaningful Current Ratio only.
FLDM' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 4.35 Max: 8.73
Current: 3.28
1.13
8.73
Quick Ratio 2.60
FLDM's Quick Ratio is ranked higher than
58% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. FLDM: 2.60 )
Ranked among companies with meaningful Quick Ratio only.
FLDM' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 3.87 Max: 8.11
Current: 2.6
0.86
8.11
Days Inventory 153.31
FLDM's Days Inventory is ranked lower than
75% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. FLDM: 153.31 )
Ranked among companies with meaningful Days Inventory only.
FLDM' s Days Inventory Range Over the Past 10 Years
Min: 102.81  Med: 149.83 Max: 443.32
Current: 153.31
102.81
443.32
Days Sales Outstanding 51.06
FLDM's Days Sales Outstanding is ranked higher than
66% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. FLDM: 51.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLDM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.06  Med: 84.55 Max: 124.82
Current: 51.06
51.06
124.82
Days Payable 31.47
FLDM's Days Payable is ranked lower than
73% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. FLDM: 31.47 )
Ranked among companies with meaningful Days Payable only.
FLDM' s Days Payable Range Over the Past 10 Years
Min: 31.47  Med: 74.66 Max: 283.05
Current: 31.47
31.47
283.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.10
FLDM's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. FLDM: -4.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FLDM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -143.7  Med: -8.2 Max: 0
Current: -4.1
-143.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.24
FLDM's Price-to-Median-PS-Value is ranked higher than
92% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. FLDM: 0.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FLDM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 0.94 Max: 2.34
Current: 0.24
0.23
2.34
Earnings Yield (Greenblatt) % -23.65
FLDM's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. FLDM: -23.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FLDM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -28.11  Med: 0 Max: 0
Current: -23.65
-28.11
0

More Statistics

Revenue (TTM) (Mil) $104.4
EPS (TTM) $ -2.62
Beta4.10
Short Percentage of Float9.04%
52-Week Range $4.31 - 11.05
Shares Outstanding (Mil)29.21

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -2.10
EPS without NRI ($) -2.10
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)